Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 2, 2011, Pages 547-552

  Boasberg, Peter D ^a   Redfern, Charles H ^b   Daniels, Gregory A ^c   Bodkin, David ^b   Garrett, Chris R ^d,f   Ricart, Alejandro D ^e  

^a Angeles Clinic and Research Institute   (United States)

^b Sharp Clinical Oncology Research   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e PFIZER INC   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

MEK inhibitor; Neurological toxicity; Ocular toxicity; PD 0325901; Pilot study

Indexed keywords

ANTIDIARRHEAL AGENT; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE;

ABDOMINAL PAIN; ABSCESS; ACNE; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BLURRED VISION; BREAST CANCER; CLINICAL ARTICLE; COLON CANCER; COLOR VISION; CONFUSION; CONSTIPATION; DEPRESSION; DERMATITIS; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSARTHRIA; DYSPHONIA; ERYTHEMA; FATIGUE; FEMALE; FLUID THERAPY; GAIT DISORDER; HUMAN; HYPOKALEMIA; HYPOXIA; INSOMNIA; ISCHEMIC OPTIC NEUROPATHY; LIMB PAIN; MALE; MELANOMA; MEMORY DISORDER; MENTAL HEALTH; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYOSITIS; NAUSEA; NECK PAIN; NEUROLOGIC DISEASE; OPHTHALMOPLEGIA; PATIENT COMPLIANCE; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; SIDE EFFECT; SKIN ABSCESS; STOMATITIS; SYNCOPE; SYSTEMIC THERAPY; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; BREAST NEOPLASMS; COHORT STUDIES; COLONIC NEOPLASMS; DIPHENYLAMINE; EARLY TERMINATION OF CLINICAL TRIALS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; EYE DISEASES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUSCULOSKELETAL DISEASES; NEOPLASM STAGING; NEUROTOXICITY SYNDROMES; PILOT PROJECTS;

EID: 79960921963     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1620-1     Document Type: Article

References (33)

1. PM Lorusso AA Adjei M Varterasian, et al. 2005 Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies J Clin Oncol 23 5281 5293 10.1200/JCO.2005.14.415 16009947 10.1200/JCO.2005.14.415 1:CAS:528:DC%2BD2MXpslOrtL8%3D (Pubitemid 46206982)
2. JF Ohren H Chen A Pavlovsky, et al. 2004 Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition Nat Struct Mol Biol 11 1192 1197 10.1038/nsmb859 15543157 10.1038/nsmb859 1:CAS:528:DC%2BD2cXhtVens7jM
3. J Rinehart AA Adjei PM Lorusso, et al. 2004 Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer J Clin Oncol 22 4456 4462 10.1200/JCO.2004.01.185 15483017 10.1200/JCO.2004.01.185 1:CAS:528: DC%2BD2cXhtFWqt77L (Pubitemid 41185111)
4. PJ Roberts CJ Der 2007 Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 3291 3310 10.1038/sj.onc.1210422 17496923 10.1038/sj.onc.1210422 1:CAS:528: DC%2BD2sXlt1Wktb4%3D (Pubitemid 46763022)
5. MM McKay DK Morrison 2007 Integrating signals from RTKs to ERK/MAPK Oncogene 26 3113 3121 10.1038/sj.onc.1210394 17496910 10.1038/sj.onc.1210394 1:CAS:528:DC%2BD2sXlt1Wkt7g%3D (Pubitemid 46763008)
6. R Seger NG Ahn J Posada, et al. 1992 Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells J Biol Chem 267 14373 14381 1321146 1:CAS:528:DyaK38XlsVKjsr0%3D
7. R Hoshino Y Chatani T Yamori, et al. 1999 Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors Oncogene 18 813 822 9989833 10.1038/sj.onc.1202367 1:CAS:528:DyaK1MXht1eht70%3D (Pubitemid 29080340)
8. JA McCubrey M Milella A Tafuri, et al. 2008 Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors Curr Opin Investig Drugs 9 614 630 18516761 1:CAS:528:DC%2BD1cXotlGhtb0%3D (Pubitemid 351777165)
9. JS Sebolt-Leopold 2008 Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway Clin Cancer Res 14 3651 3656 10.1158/1078-0432.CCR-08-0333 18559577 10.1158/1078-0432.CCR- 08-0333 1:CAS:528:DC%2BD1cXntlWkurc%3D
10. PM Lorusso SS Krishnamurthi JJ Rinehart, et al. 2010 Phase I pharmacokinetic and pharmacodynamic study of the oral MEK inhibitor PD-0325901 in patients with advanced cancers Clin Cancer Res 16 1924 1937 10.1158/1078-0432.CCR-09-1883 20215549 10.1158/1078-0432.CCR-09-1883 1:CAS:528:DC%2BC3cXjtFyhurk%3D
11. TT Chen 1997 Optimal three-stage designs for phase II cancer clinical trials Stat Med 16 2701 2711 10.1002/(SICI)1097-0258(19971215)16:23<2701:: AID-SIM704>3.0.CO;2-1 9421870 10.1002/(SICI)1097-0258(19971215)16:23<2701: :AID-SIM704>3.0.CO;2-1 1:STN:280:DyaK1c%2FotlKnug%3D%3D (Pubitemid 27496916)
12. AA Adjei RB Cohen W Franklin, et al. 2008 Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers J Clin Oncol 26 2139 2146 10.1200/JCO.2007.14.4956 18390968 10.1200/JCO.2007.14.4956 1:CAS:528:DC%2BD1cXms1OrtL8%3D
13. Agarwal R, Banerji U, Camidge DR et al (2008) The first-in-human study of the solid oral dosage form of AZD6244 (ARRY-142886): a phase I trial in patients (pts) with advanced cancer. J Clin Oncol 26:15S (supplement; abstract 3535)
14. Lang I, Adenis A, Boer K et al (2008) AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy. J Clin Oncol 26:15S (supplement; abstract 4114)
15. Dummer R, Robert C, Chapman PB et al (2008) AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. J Clin Oncol 26:15S (supplement; abstract 9033)
16. Tzekova V, Cebotaru C, Ciuleanu TE et al (2008) Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26:15S (supplement; abstract 8029)
17. Lucas AS, Cohen EE, Cohen RB et al (2010) Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements. J Clin Oncol 28:15s (supplement; abstract 5536)
18. Delord J, Houede N, Awada A et al (2010) First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors. J Clin Oncol 28:15s (supplement; abstract 2504)
19. Infante JR, Fecher LA, Nallapareddy S et al (2010) Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J Clin Oncol 28:15s (supplement; abstract 2503)
20. Borad MJ, Akerele CE, Ramanathan RK et al (2010) Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors. J Clin Oncol 28:15s (supplement; abstract 2505)
21. ET Keller Z Fu M Brennan 2004 The role of Raf kinase inhibitor protein (RKIP) in health and disease Biochem Pharmacol 68 1049 1053 10.1016/j.bcp.2004. 04.024 15313400 10.1016/j.bcp.2004.04.024 1:CAS:528:DC%2BD2cXmslOnsr4%3D (Pubitemid 39094269)
22. JS Katz GI Wolfe DK Burns WW Bryan JL Fleckenstein RJ Barohn 1996 Isolated neck extensor myopathy: a common cause of dropped head syndrome Neurology 46 917 921 8780064 1:STN:280:DyaK28zntlOksQ%3D%3D (Pubitemid 26134626)
23. H Askmark Y Olsson S Rossitti 2000 Treatable dropped head syndrome in hypothyroidism Neurology 55 896 897 10994024 1:STN:280:DC%2BD3M%2FgvVCksQ%3D%3D
24. KJ Goh KT Wong CT Tan 2000 Myopathic dropped head syndrome: a syndrome of mixed aetiology J Clin Neurosci 7 334 336 10938615 10.1054/jocn.1999.0209 1:STN:280:DC%2BD3cvis12kug%3D%3D (Pubitemid 30612962)
25. R Beekman CC Tijssen LH Visser RL Schellens 2002 Dropped head as the presenting symptom of primary hyperparathyroidism J Neurol 249 1738 1739 10.1007/s00415-002-0898-7 12529801 10.1007/s00415-002-0898-7 (Pubitemid 36269271)
26. K Frebel S Wiese 2006 Signalling molecules essential for neuronal survival and differentiation Biochem Soc Trans 34 1287 1290 17073803 10.1042/BST0341287 1:CAS:528:DC%2BD28XhtFKgtb3N (Pubitemid 46769039)
27. A Galy B Neron N Planque S Saule A Eychene 2002 Activated MAPK/ERK kinase (MEK-1) induces transdifferentiation of pigmented epithelium into neural retina Dev Biol 248 251 264 10.1006/dbio.2002.0736 12167402 10.1006/dbio.2002.0736 1:CAS:528:DC%2BD38XlvFSqtLY%3D (Pubitemid 35002087)
28. RD Fields F Eshete S Dudek N Ozsarac B Stevens 2001 Regulation of gene expression by action potentials: dependence on complexity in cellular information processing Novartis Found Symp 239 160 172 11529310 10.1002/0470846674.ch13 1:CAS:528:DC%2BD38XitFOls70%3D (Pubitemid 33599040)
29. W Ma D Maric BS Li, et al. 2000 Acetylcholine stimulates cortical precursor cell proliferation in vitro via muscarinic receptor activation and MAP kinase phosphorylation Eur J Neurosci 12 1227 1240 10.1046/j.1460-9568.2000. 00010.x 10762352 10.1046/j.1460-9568.2000.00010.x 1:STN:280: DC%2BD3c3isFGnsQ%3D%3D (Pubitemid 30224227)
30. HF Kramer LJ Goodyear 2007 Exercise, MAPK, and NF-kappaB signaling in skeletal muscle J Appl Physiol 103 388 395 10.1152/japplphysiol.00085.2007 17303713 10.1152/japplphysiol.00085.2007 1:CAS:528:DC%2BD2sXovFKisb8%3D (Pubitemid 47092316)
31. T Ravingerova M Barancik M Strniskova 2003 Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology Mol Cell Biochem 247 127 138 10.1023/A:1024119224033 12841640 10.1023/A:1024119224033 1:CAS:528:DC%2BD3sXksFWgtLc%3D (Pubitemid 36798517)
32. AP Brown TC Carlson CM Loi MJ Graziano 2007 Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration Cancer Chemother Pharmacol 59 671 679 10.1007/s00280-006-0323-5 16944149 10.1007/s00280-006-0323-5 1:CAS:528:DC%2BD2sXhvVeitbY%3D (Pubitemid 46295133)
33. Rosen LS, Galatin P, Fehling JM et al (2008) A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors. J Clin Oncol 26:15S (supplement; abstract 14585)